All Posts

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

We're coming down to the final weeks of Q1 2023. This past week XBI finished green up ~1%, although it still sits in the mid $70's. See...

Summary: The CDTX PDUFA for Rezafungin to treat candidemia and invasive candidiasis is scheduled for March 22 Positive Phase 3 data from...

Summary: The American Association for Cancer Research (AACR) 2023 Annual Meeting will take place from April 14-19, 2023, abstracts...

Each week we're posting a countdown of the remaining catalysts left in Q1! Last week was a rough week for biotech's with XBI finishing...

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

Summary: The ACAD Trofinetide PDUFA is expected this Sunday March 12, 2023 Will we see an early decision before the weekend? See our full...

First published 3/6/23 - currently in progress Summary: ESPR CLEAR outcomes data from NEXLETOL trial reported over the weekend at ACC.23...

Last week was a green week for XBI (biotech ETF), which finished the week up +2.3%, see the biggest news from last week, including a full...

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...